The management approaches to dyskinesia vary from country to country.
Many Parkinson's disease (PD) patients treated with levodopa develop motor fluctuations and/or dyskinesia. This large, retrospective study was conducted to compare the prevalence and treatment of dyskinesia in PD patients in seven countries. A total of 380 physicians were interviewed and completed patient record forms retrospectively for their last 5 patients with dyskinesia (total 1,900). The overall prevalence of dyskinesia in PD patients was 34%, but the rate varied from 24 to 51% according to geographical location. This study showed that 51.0% of Japanese physicians and 50.6% of UK physicians were dissatisfied with current treatment strategies for dyskinesia. Regardless of geographical location, physicians were dissatisfied with the current treatment strategies for dyskinesia.
Woitalla
Dirk
D
Department of Neurology, St. Josef Hospital, Ruhr University, Bochum, Germany. dirk.woitalla@ruhr-uni-bochum.de
Mueller
Thomas
T
Russ
Hermann
H
Hock
Klaus
K
Haeger
Doris-Anita
DA
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D019091:Critical Pathways; D003431:Cross-Cultural Comparison; D003430:Cross-Sectional Studies; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000453:epidemiology; D005060:Europe; D006801:Humans; D015994:Incidence; D007564:Japan; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology; D012017:Referral and Consultation / Q000706:statistics & numerical data; D012189:Retrospective Studies; D014481:United States
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa